CVKD · Cadrenal Therapeutics, Inc. · Financials
$1.22
+0.02 (+1.58%)
At close · Sep 9
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$4.28M
Shares
3.57M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$13.24M
-24.3%
FY2025
Diluted EPS
-$6.64
+23.9%
FY2025
Operating Cash Flow
-$12.6M
-71.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | — | — | $220.1K | $220.1K | |
| $705.15K | $4.1M | $4.21M | $4.08M | $200K | |
| $8.82M | $9.35M | $6.75M | $3.55M | — | |
| $11.65M | $13.46M | $10.96M | $7.63M | — | |
| -$11.65M | -$13.46M | -$10.96M | -$7.63M | — | |
| — | — | — | $3534 | — | |
| $109.89K | $223.82K | $309.25K | -$724.24K | — | |
| -$11.54M | -$13.24M | -$10.65M | -$8.36M | — | |
| USD/shares | -$4.86 | -$6.64 | -$8.73 | -$9.29 | — |
| USD/shares | -$4.86 | -$6.64 | -$8.73 | -$9.29 | — |
| shares | — | 1.99M | 1.22M | 899.47K | — |
| shares | — | 1.99M | 1.22M | 899.47K | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.12×
EV/EBIT
—
P/E (TTM)
—
Peer median 0.24×
Peer medians compare against the 153 similar-size Biotechnology companies (of 537 listed).
Key facts
CIK
1937993
CUSIP
127636207
13F (30d)
13 filings
13 filers
Visit website
Investor relations